Pharmaceuticals News and Research

RSS

Scientists reveal first-ever glimpse of complete kappa opioid receptor structure

At the molecular level, drugs like salvinorin A (the active ingredient of the hallucinogenic plant Salvia divinorum) work by activating specific proteins, known as receptors, in the brain and body.

22 Mar 2012

Cannabinoid drugs can directly inhibit HIV in late-stage AIDS

Mount Sinai School of Medicine researchers have discovered that marijuana-like chemicals trigger receptors on human immune cells that can directly inhibit a type of human immunodeficiency virus (HIV) found in late-stage AIDS, according to new findings published online in the journal PLoS ONE.

21 Mar 2012

Fat-enclosed nanoparticles can directly irradiate brain tumor

For the past 40 years, radiation has been the most effective method for treating deadly brain tumors called glioblastomas. But, although the targeting technology has been refined, beams of radiation still must pass through healthy brain tissue to reach the tumor, and patients can only tolerate small amounts before developing serious side effects.

21 Mar 2012

Roundup: States face new revenue downturn; Calif. county has disparities in life expectancy

Revenues in most U.S. states increased in the fourth quarter of 2011, but their recent surge is tapering off, as they grew just 2.7 percent from the final quarter of 2010, according to a report released on Monday. "This is a noticeable slowdown from the 11.1 (percent) and 6.1 percent year-over-year growth reported in the second and third quarters of 2011, respectively," the Rockefeller Institute, a think tank that closely watches states' revenues, said in the report.

21 Mar 2012

TACT believes that Halo's HT-100 may effectively treat DMD

Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that the TREAT-NMD Advisory Committee on Therapeutics (TACT) has reviewed HT-100, Halo's drug candidate for Duchenne muscular dystrophy (DMD), and believes the compound has potential based on the proposed mechanism.

21 Mar 2012

DIAN-TTU to receive $4.2M Alzheimer's Association research grant

The Alzheimer's Association announced today the awarding of its largest ever research grant – nearly $4.2 million dollars over four years – to the Dominantly Inherited Alzheimer's Network–Therapeutic Trials Unit (DIAN-TTU), based at Washington University School of Medicine in St. Louis, to enable the program to move forward more quickly with innovative drug and biomarker trials in people with genetically-based, young-onset Alzheimer's disease.

21 Mar 2012

Alzheimer's Association awards $4.2M grant to DIAN-Therapeutic Trials Unit

Washington University School of Medicine in St. Louis has received nearly $4.2 million from the Alzheimer's Association to accelerate the launch of the first clinical trials to prevent the symptoms of Alzheimer's disease.

21 Mar 2012

GeoVax enters into definitive agreements to sell Series A convertible preferred stock

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series A convertible preferred stock at an aggregate purchase price of approximately $2.2 million and Series A warrants to purchase up to an aggregate of 2,933,333 shares of GeoVax common stock with an exercise price of $1.00 per share and a term of five years.

21 Mar 2012

Noven completes LDMP Phase 3 studies on menopausal VMS

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has completed the Phase 3 clinical development program evaluating low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms (VMS) associated with menopause.

21 Mar 2012

Enzo Life Sciences, Cosmo Bio expand business arrangement

Enzo Biochem Inc. announced today an expanded business arrangement between its wholly owned subsidiary, Enzo Life Sciences, and Tokyo-based Cosmo Bio Co., Ltd..

21 Mar 2012

FDA approves Watson's generic BONIVA ANDA to treat osteoporosis in women

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc. has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Ibandronate 150mg tablets, the generic equivalent to Roche's BONIVA tablets.

21 Mar 2012

PSG closes acquisition of Artemetrx

Pharmaceutical Strategies Group, LLC, America's largest independent pharmacy benefits consulting firm, has closed on its acquisition of Artemetrx Health Resources, the company announced today.

21 Mar 2012

Lexicon receives FDA Orphan Drug designation for telotristat etiprate to treat carcinoid syndrome

Lexicon Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted its request for Orphan Drug designation for telotristat etiprate (LX1032) for the treatment of carcinoid syndrome.

21 Mar 2012

Positive data from Aerpio's AKB-9778 Phase 1 trial on DME

Aerpio Therapeutics, a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease, today announced positive data from its Phase 1 trial of AKB-9778 for the treatment of diabetic macular edema.

21 Mar 2012

IGI fourth quarter total revenues increase 21% to $2.1M

IGI Laboratories, Inc., a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the fourth quarter and year ended December 31, 2011.

21 Mar 2012

Indian patent court licenses generic copy of Bayer’s blockbuster anticancer drug

Last week an Indian patent court shocked the $600 billion global pharmaceutical business by ordering Bayer, the German health care giant, to allow a tiny Indian generic drug company to sell cheap copies of the blockbuster cancer drug Nexavar – even though everyone agrees that the drug is protected by a patent. Instead, the court decided that Bayer had an obligation to make Nexavar available to people in India who needed it.

20 Mar 2012

Mylan receives final FDA approval for generic Boniva ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ibandronate Sodium Tablets, 150mg.

20 Mar 2012

Acelrx fourth quarter net loss increases to $6.4 million

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2011.

20 Mar 2012

Ampio receives U.S. patent allowance for lead drug Ampion

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs, licensing distribution of these drugs and engaged in further drug development, today announced that it has received notice of allowance from the US Patent Office of an additional patent that complements and expands its anti inflammatory patent portfolio for its lead drug Ampion.

20 Mar 2012

Positive data from XENTION's XEN-D0103 phase 1 trial on AF

XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.

20 Mar 2012